HeartFlow Inc. has struck a deal with medtech giant, Philips Healthcare, to widen the sales reach of its its HeartFlow FFRct Analysis technology for diagnosing coronary heart disease (CAD). Under the terms of the agreement, the Dutch healthcare group will promote the use of HeartFlow's technology alongside its own coronary fractional flow reserve (FFR), instant wave-free ratio (iFR) and intravascular ultrasound (IVUS) advanced catheters that it gained through its $1.2bn acquisition of Volcano Corp. back in 2015.
Philips, HeartFlow Cut FFR R&D, Commercial Deal
HeartFlow has signed another deal with one of the medical imaging giants to promote its HeartFlow FFRct Analysis technology for diagnosing coronary heart disease, this time with Dutch group Philips. The collaboration will further expand Philips' intravascular imaging offerings, a space in which it is focused on becoming a leader.